Why Moderna Stock Was So Healthy This Week
(NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock. Investors piled into its shares over the week, sending it to a more than 12% gain over the period, according to data compiled by S&P Global Market Intelligence. Positive news from the lab was a significant factor in this.
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical trial the vaccine, developed using Moderna's signature mRNA-based approach, produced a more robust immune response than a standard flu jab currently available on the market.
Image source: Getty Images.
Source Fool.com
Moderna Inc. Stock
€43.14
0.090%
With 7 Buy predictions and 8 Sell predictions the community is currently undecided on Moderna Inc..
The target price of 21 € compared with the current price of 43.14 € for the stock indicates a negative potential of -51.32%.
